Skip to Content
Merck
  • LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer.

LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer.

Biochimica et biophysica acta. Molecular basis of disease (2018-05-12)
Hao-Xuan Wu, Xi Cheng, Xiao-Qian Jing, Xiao-Pin Ji, Xian-Ze Chen, Ya-Qi Zhang, Yong-Gang He, Kun Liu, Feng Ye, Han-Xing Sun, Hao-Ji Gao, Zi-Jia Song, Huo Wu, Xiao-Jian Zhang, Tao Zhang, Ren Zhao
ABSTRACT

Leukemia inhibitory factor receptor (LIFR) has been documented as a cancer promoter and to be present at high levels in various types of tumor tissues. In our search for molecules prognostic of colorectal cancer (CRC), we found high levels of LIFR in CRC tissue samples. Further analyses revealed that LIFR was indeed prognostic of CRC patient survival, and was associated with tumor size, lymphatic metastasis and stages. LIFR was found to promote tumor growth, metastasis and angiogenesis both in vitro and in vivo. High levels of LIFR in CRC facilitated proliferation and migration of endothelial cells, resulting in an increase in angiogenic activity. Moreover, interleukin 8 (IL-8) was found to play a role in the LIFR induced angiogenesis. IL-8 levels were correlated with LIFR levels in CRC tissues, whereas depletion of IL-8 led to a reduced angiogenic activity of LIFR in CRC cells. In addition, LIFR increased phosphorylation level of Erk, which regulates il-8 transcription. We conclude that LIFR is possibly a valuable prognostic marker for CRC. Our results also implicate a mechanism by which LIFR regulates tumor angiogenesis through Erk/IL-8 pathway, and that LIFR could be a potential therapeutic target for CRC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human LIFR